Canagliflozin CV Benefits Appear to Be Dose-Dependent ...Middle East

Medscape - News
Canagliflozin CV Benefits Appear to Be Dose-Dependent
A post-hoc analysis of the pivotal CANVAS trial shows those receiving higher dose canagliflozin are more likely to experience the cardiovascular benefits associated with the drug. Medscape Medical News

Read More Details
Finally We wish PressBee provided you with enough information of ( Canagliflozin CV Benefits Appear to Be Dose-Dependent )

Also on site :



Latest News